Importing medicines into Northern Ireland

AI Summary

This guidance document details the UK MHRA's implementation of a European Commission Notice regarding the supply of human and veterinary medicines to Northern Ireland and other historically UK-dependent markets. The regulatory framework, rooted in EU Directives 2001/83/EC and 2001/82/EC, extends specific exemptions to ensure stable medicine access. Under these provisions, the MHRA allows medicinal products to be tested and released by a Qualified Person at sites within either the UK or the EU, provided equivalent standards are maintained and establishments are supervised. This policy applies to products approved both before and after January 31, 2021. The MHRA assumes that all pharmaceutical companies will utilize these regulatory flexibilities to maintain existing supply chains and manufacturing logistics while transitioning to long-term compliance measures. Consequently, enforcement is based on the automatic application of these flexibilities to all products. Required actions for companies: No proactive notification is necessary if the company intends to use these flexibilities. However, if a company chooses not to apply these exemptions to their portfolio, they must formally notify the MHRA via email. The notification must include specific product details, including the marketing authorization number and the rationale for opting out. This reporting obligation ensures that the MHRA and European Medicines Agency can effectively monitor the supply landscape in Northern Ireland.